A German man, known as Berlin 2 (B2), remains in remission from HIV six years after a stem cell transplant, marking the seventh known long-term remission case.
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...
Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have announced a global collaboration to develop and ...
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...
As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
Research is important to us for many reasons. Sometimes, for example, research results in a new treatment (e.g., Alexander ...
But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...
Tech-savvy parents to be are using IVF and screening embryos to build families in ways that were unimaginable a few short years ago.
After releasing two gene-edited rice varieties in May this year, scientists are now focusing on developing GE varieties of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback